Pemvidutide cuts heavy drinking days in Phase 2 alcohol use disorder trial
Pemvidutide reduced heavy drinking days in Altimmune’s Phase 2 RECLAIM trial, but gastrointestinal side effects and limited patient diversity remain.
Pharma & Biotech
Pharma & Biotech
How Clearmind Medicine is positioning CMND-100 within the emerging non-hallucinogenic neuroplastogen market
Clearmind Medicine is advancing CMND-100 in Alcohol Use Disorder. Discover why the non-hallucinogenic neuroplastogen market is gaining attention.
Pharma & Biotech
Why DemeRx’s FDA-cleared DMX-1001 IND could matter for alcohol use disorder drug development
Find out how DemeRx’s DMX-1001 IND acceptance could reshape alcohol use disorder drug development and what risks remain.